Evofem Biosciences, Inc.
EVFM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $955 | $309 | $3,728 | $49,222 |
| - Cash | $741 | $580 | $2,769 | $7,732 |
| + Debt | $45,967 | $43,373 | $71,128 | $115,682 |
| Enterprise Value | $46,181 | $43,102 | $72,087 | $157,172 |
| Revenue | $19,363 | $18,218 | $16,837 | $8,244 |
| % Growth | 6.3% | 8.2% | 104.2% | – |
| Gross Profit | $15,529 | $11,706 | $12,422 | $4,189 |
| % Margin | 80.2% | 64.3% | 73.8% | 50.8% |
| EBITDA | -$6,920 | -$16,066 | -$82,078 | -$165,778 |
| % Margin | -35.7% | -88.2% | -487.5% | -2,010.9% |
| Net Income | -$8,860 | $52,979 | -$76,698 | -$205,192 |
| % Margin | -45.8% | 290.8% | -455.5% | -2,489% |
| EPS Diluted | -0.092 | 0.051 | -164.59 | -2,962.49 |
| % Growth | -280.9% | 100% | 94.4% | – |
| Operating Cash Flow | -$3,885 | -$8,968 | -$70,410 | -$146,667 |
| Capital Expenditures | -$14 | -$4 | -$341 | -$2,939 |
| Free Cash Flow | -$3,899 | -$8,972 | -$70,751 | -$149,606 |